Building upon the concept used by cardiologists in heart failure, for the first time, nephrologists and endocrinologists can apply the principles of three established “pillars of therapy”—ACEi or ARB (at maximally tolerated doses), SGLT2 inhibitors, and finerenone (NS-MRA)—to maximally slow declines in kidney function, as shown in Figure 4. Here, SLC5A2 is linked to heart failure.